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Characterization of Nanodiamond-
based anti-HIV drug Delivery to the 
Brain
Upal Roy1,4, Vadym Drozd2, Andriy Durygin2, Jesse Rodriguez  3, Paul Barber4, Venkata Atluri  4, 
Xiaohua Liu5, Thomas G. Voss6, Surendra Saxena2 & Madhavan Nair4
Human Immunodeficiency Virus Type 1 (HIV-1) remains one of the leading causes of death worldwide. 
Present combination antiretroviral therapy has substantially improved HIV-1 related pathology. 
However, delivery of therapeutic agents to the HIV reservoir organ like Central nervous system (CNS) 
remains a major challenge primarily due to the ineffective transmigration of drugs through Blood Brain 
Barrier (BBB). The recent advent of nanomedicine-based drug delivery has stimulated the development 
of innovative systems for drug delivery. In this regard, particular focus has been given to nanodiamond 
due to its natural biocompatibility and non-toxic nature–making it a more efficient drug carrier than 
other carbon-based materials. Considering its potential and importance, we have characterized 
unmodified and surface-modified (-COOH and -NH2) nanodiamond for its capacity to load the anti-
HIV-1 drug efavirenz and cytotoxicity, in vitro. Overall, our study has established that unmodified 
nanodiamond conjugated drug formulation has significantly higher drug loading capacity than surface-
modified nanodiamond with minimum toxicity. Further, this nanodrug formulation was characterized 
by its drug dissolution profile, transmigration through the BBB, and its therapeutic efficacy. The present 
biological characterizations provide a foundation for further study of in-vivo pharmacokinetics and 
pharmacodynamics of nanodiamond-based anti-HIV drugs.
HIV-1 infection remains one of the leading causes of mortality in the world. Although the development of combi-
nation antiretroviral therapy (cART) has significantly improved the mean lifespan of HIV-1 infected patients, the 
virus persists inside reservoir organs, such as the CNS and lymphoid tissues1,2. cART dosing regimens also show 
limitations based on distribution, metabolism, drug stability, and limited penetration into the CNS. This com-
monly results in suboptimal adherence, increased risk for treatment failure and development of viral resistance3. 
Moreover, drug characteristics are highly complex and differ substantially in chemical composition, molecular 
size, and protein binding. Therefore, drugs that provide a profound beneficial effect can also exhibit adverse 
side effect. Drug-induced toxicities and pharmacokinetic limitations commonly result in poor compliance and 
disease-related complications, including HIV-1 associated neurological disorders (HAND)2,4. HAND is perhaps 
the most common manifestation of HIV-1 pathogenesis that causes cognitive impairment and other CNS-related 
disorders5–9. Even with the advent of cART, over 40% of HIV-1 infected patients experience neurological com-
plications9. Moreover, rates of HAND are likely to rise in the coming years as anti-HIV-1 therapies continue to 
extend the lifespan of patients. Currently, treatment options for HAND remain limited. Due to its poor penetra-
tion into the CNS, even potent antiretroviral therapy can only attenuate the progression of HAND. Eliminating 
HIV-1 reservoirs in the CNS will greatly increase the quality of life and lifespan of infected patients10. Therefore, 
the development of antiretroviral medicines to improve drug delivery into the CNS will continue to be an active 
and growing research field.
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Nanomedicine-based drug delivery has revolutionized the targeted therapy field. With the help of nanotech-
nology, current therapeutic drugs can now be incorporated into a variety of biocompatible nanocarriers, thereby, 
improving their overall pharmacological properties. These formulations can then be further modified to deliver 
drugs to site-specific targets11 Presently, the most promising nanomaterial for drug delivery applications is nano-
crystalline diamond or “Nanodiamond” (ND)12. The ND surface possesses an assortment of functional groups, 
most of which are oxygenated moieties, including carboxylic acid, lactone, ketone, ether, hydroxyl, etc. The nat-
ural biocompatibility, structural stability, and non-toxic nature of ND make it a widely applicable biomedical 
application12–17. Previous studies have demonstrated its capability as a drug carrier of doxorubicin, purvalanol A, 
4-hydroxytamoxifen, and dexamethasone for human colon cancer, liver cancer, breast cancer and blood cancer 
therapies, respectively. Furthermore, these studies also indicated that ND possesses major cancer drug loading 
and sustained release capacities without producing any inflammatory reaction in human cells18–22. Previous mito-
chondrial function (MTT) and DNA fragmentation assays indicated that ND is not cytotoxic to many different 
human cell types16. Furthermore, ND has distinct advantages compared to other carbon-based nanomaterials, 
such as carbon nanotubes and nanographene, which have shown toxicity in many other studies. Moreover, they 
are not dispersed in water, which makes it difficult to use these excipients in nanoformulations23–25. On the con-
trary, the surface electrostatic potential of ND, which causes water to be drawn to surface, allows for the adsorp-
tion of drug molecules13. Therefore, ND provides an opportunity to use this material for anti-HIV-1 drugs that are 
not stable or dispersible in water. Considering its inherent characteristics, ND has been used for the delivery of 
many different therapeutic molecules, including drug, siRNA, hormones, proteins, and vitamins, without altering 
the biological activity of the molecule13,26–31. ND has the unique capability to solubilize water-insoluble drugs, 
making them more effective in repackaging hydrophobic anti-HIV-1 drugs. Finally, ND has also been shown to 
increase drug stability and prolong drug circulation time32.
In the present study, one cART drug, efavirenz (a non-nucleoside reverse transcriptase inhibitor or NNRTI, 
EFV), was formulated with unmodified ND or also referred as ND, -COOH surface modified ND (ND-COOH), 
and -NH2 surface modified ND (ND-NH2), respectively. As a free drug, EFV suffers from poor bioavailability 
due to blood plasma protein binding (99.5% binding)33–35. The small size and minimal toxicity of ND make the 
material an ideal candidate for improving drug delivery to the CNS. Furthermore, functionalized ND has the 
capacity to transport anti-HIV-1 drugs across the Blood-Brain Barrier (BBB). By applying ND towards drug 
delivery to treat HIV-1 CNS reservoirs, we have established that the conjugation of EFV with functionalized ND 
will substantially increase its therapeutic efficacy.
Results
Characterization of ND, ND-COOH, and ND-NH2. To prepare the ND conjugated nanodrug, well-char-
acterized ND was taken from different batches of ND powder prepared and characterized as per previously pub-
lished protocol36. Figure 1 shows results of transmission electron microscopy (TEM), X-ray diffraction (XRD) 
and Raman spectroscopy characterization of nanodiamond powders. According to TEM, the average particle 
size of nanodiamond was 5 nm (3–6 nm as per manufacturer’s specifications) (Fig. 1A–C). The TEM images also 
showed that the primary diamond particles were partly agglomerated. Measured XRD pattern (Mo Kα-radiation) 
of nanodiamond powder was a characteristic for good quality nanodiamonds. Two broad peaks correspond to 
diffraction from atomic planes with Miller indices (111) and (220) of the cubic diamond structure. Figure 1E 
shows Raman spectra of three ND that were used in this study: (a) unmodified, (b) –COOH surface  modified 
and (c) –NH2 surface modified surface modifications. Raman spectra were collected using Ar+ ion laser excita-
tion (λ = 514.5 nm) and show vibrational feature at 1326 cm−1 which were a first-order diamond peak. The peak 
at 1619 cm−1 was a superposition of sp2 carbon (G-band) and OH groups on the surface. Both XRD and Raman 
study showed no graphitization of –COOH, -NH2 modified ND. Nonetheless, it was important to consider that 
the overall formulation should be nontoxic to neuronal cells to consider its potential for further study.
ND-COOH induced more ROS compared to ND and ND-NH2 on SK-N-MC (ROS assay). In order 
to determine which formulation would be ideal for anti-HIV-1 drug delivery, it was important to observe whether 
any of these formulations by itself can induce ROS production to neuronal cells. In this regard, neuroblastoma 
cells (SK-N-MC) were treated with different concentrations of ND, ND-COOH, and ND-NH2, respectively, to 
observe the effect of these formulations on ROS production. As explained in the (Fig. 2), ND, ND-COOH, and 
ND-NH2 had a varied effect on SK-N-MC with respect to ROS production. Compared to antioxidant (catalase) 
and positive control (H2O2), ND and ND-NH2 formulation treatment did not exhibit any significant changes in 
ROS production at the different concentrations tested in this study. Whereas, ND-COOH treated cells showed 
significantly higher ROS release in all tested concentrations on SK-N-MC indicating overall cytotoxicity. Based 
on ROS assay, it was observed that ND-COOH formulation was substantially inducing more ROS production to 
SK-N-MC compared to ND and ND-NH2.
ND was found to be nontoxic to SK-N-MC cells compared to ND-COOH and ND-NH2 (MTS 
assay). ND, ND-COOH, and ND-NH2 were also evaluated for their effect on the cell viability of SK-N-MC 
(Fig. 3). The formulations were introduced separately at different concentrations (0.5–1000 µg/ml) to SK-N-MC 
and incubated for 24 h; MTS assay was then performed as per the manufacturer’s instruction (G3582, Promega, 
Madison, WI, USA). Figure 3 showed that SK-N-MC cell viability did not significantly change with increasing 
concentration of ND or ND-NH2 compared to control. Whereas, ND-COOH treatment had a significant effect 
on reducing cell viability at concentrations higher than 40 µg/ml. Considering the chemical characterization, 
cytotoxicity, and ROS assay, it was observed that ND and ND-NH2 were more biocompatible and less toxic to 
neuronal cells.
www.nature.com/scientificreports/
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ND adsorbed comparatively more drug than ND-COOH. Adsorption isotherm of EFV on unmod-
ified ND (milligrams of EFV absorbed per 1 g of ND) (in blue) as a function of Ceq (concentration of adsorbate 
in solution which is equilibrium with ND) is shown in (Fig. 4). The other formulations ND-NH2 (in red) and 
Figure 1. Characterization of ND: TEM images of (A) as-received ND, (B) –COOH and (C) –NH2 modified 
nanodiamonds. (D) Powder X-ray diffraction patterns of as-received ND in comparison with –COOH and 
–NH2 functional groups modified ND powders. The reflecting atomic planes of the diamond structure are 
denoted by Miller indices. (E) Raman spectra of (a) as-received ND, (b) –COOH and (c) –NH2 modified 
nanodiamonds.
Figure 2. Effect of ND, ND-COOH, & ND-NH2 on ROS production on SK-N-MC cells: Three formulations 
were exposed at different concentrations (10–1000 µg/ml) to SK-N-MC cells for 24 h. At the end of incubation, 
ROS production was measured in treated cells compared to untreated cells. The ROS production was measured 
in terms of mean ± SE relative fluorescence units (RFU) of eight independent experimental values. The statistical 
significance between untreated (ND) and ND-COOH treated cells were expressed as p values (**p < 0.001, 
***p < 0.0003). There was no statistical significance between untreated (ND) and ND-NH2 groups.
www.nature.com/scientificreports/
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ND-COOH (in black) were also presented in Fig. 4 to demonstrate comparative adsorption of EFV by these 
formulations. Experimental points were fit by Langmuir adsorption model. This empirical model suggests 
homogeneous monolayer absorption of the drug on the surface of the adsorbent. Maximum adsorption capacity 
obtained from Langmuir isotherm is 161 mg EVF/g for unmodified ND. However, this value was not achieved 
experimentally due to the low solubility of EFV. KL constant which characterizes the bonding strength between 
the adsorbate (EFV) and the adsorbent (ND) is 23 mL/mg. In this regard, the relatively low value of KL sug-
gested easy desorption of EFV from the ND. Comparative analysis of EFV adsorption on ND, ND-COOH, and 
ND-NH2, respectively, indicated that with respect to time and increasing concentration, there was quite a dis-
tinction between the three formulations. In Fig. 4, unmodified ND and ND-NH2 demonstrated a similar EFV 
adsorption compared to ND-COOH, which showed relatively low adsorption capacity for EFV at any given con-
centration and therefore not selected for further characterization in drug adsorption study. On the other hand, 
ND and ND-NH2 showed a similar capacity for drug loading and were nontoxic to cells. As ND-NH2 possessed a 
similar drug loading capacity and relatively similar biocompatibility as ND, therefore ND was selected for further 
in vitro characterization.
Sustained release of EFV from ND-EFV (Dissolution study). The sustained drug release profile of the 
ND-EFV formulation was determined in phosphate buffer saline (PBS) using equilibrium dialysis. The released 
drugs outside the dialysis bag were sampled at different time intervals (from 30 min up to 14 days) and measured 
by high-performance liquid chromatography (HPLC). As a positive control, equal amounts of the unformulated 
EFV (also called free drug or FD) were introduced directly to the in vitro PBS buffer, separately. Results were 
expressed as ng/ml of drug released from the ND relative to initial drug loading (Fig. 5). Compared to the FD (in 
blue), ND-EFV (in green) showed significant sustained drug release characteristics indicating improved pharma-
cokinetics of ND-EFV in vitro. This observation showed probable in vivo drug release pattern where a free drug 
Figure 3. Cytotoxicity of ND, ND-COOH, and ND-NH2 on SK-N-MC cells. The cells were treated with a 
range of concentrations (0.5–1000 µg/ml) for 24 h, separately. After incubation, MTS assay was performed and 
optical density (OD) was measured at 490nm. Graphical representation was made in terms of % survival of cells 
at different concentrations of three formulations corresponding to their OD values. Untreated cells (control) 
were considered as 100% viability and % survival was monitored based on control. The statistical significance 
between ND, ND-COOH, & ND-NH2 groups compared to control was expressed as p values (***p < 0.0001).
Figure 4. Adsorption isotherm of EFV on ND. The dotted line showed EFV adsorption by ND (blue), ND-
NH2 (red) and ND-COOH (black), respectively. The adsorption values were calculated and represented as 
experimental points by Langmuir model. Inserts showed structural formula of efavirenz drug only and ND 
suspension in PBS buffer solution, respectively.
www.nature.com/scientificreports/
5SCIENTIFIC RepoRts |  (2018) 8:1603  | DOI:10.1038/s41598-017-16703-9
is immediately released and get metabolized, whereas the ND-EFV sustained release pattern helps in CNS drug 
delivery where slow release of the drug is crucial for viral reservoir reduction. The overall chemical characteri-
zation of ND-EFV established a potential nanoformulation for anti-HIV drug carrier. Considering drug loading 
capacity of ND and possible cytotoxicity of ND-EFV at higher concentration, 40 ug/ml ND-EFV was used for 
further biological characterization.
Drug release of ND-EFV in vitro environment through BBB. ND-EFV was further tested for its drug 
delivery capacity in crossing the BBB. An in vitro BBB model was set up to mimic the biological barrier that 
impacts drug delivery to the CNS. ND-EFV (40 ug/ml) was introduced into the upper chamber of the in vitro 
BBB model and drug content was monitored at the lower chamber as it crossed the other side of the BBB from 
30 min up to day two. Unformulated EFV (40 g/ml) was also introduced in a separate setup, which served as a 
positive control. The BBB drug release study showed that unformulated EFV possesses a very robust drug release 
in  the brain side of the BBB model (Fig. 6). Nonetheless, ND-EFV specifically indicated significantly slower 
release of EFV compared to unformulated EFV. Thus, we have established that ND-EFV is a potential candidate 
for anti-HIV-1 drug delivery to the brain due to its ability to cross BBB and extend the retention time of EFV in 
the CNS.
Figure 5. Drug dissolution study of nanodrug (ND) vs. Free drug (FD) in vitro. The released drug outside of 
dialysis bag was measured from 30 min up to day 14 by HPLC. The data indicated is an average of four different 
experiments (p > 0.05).
Figure 6. Drug delivery of ND-EFV through BBB in vitro. ND-EFV (green) and FD (blue) (40 µg/ml) were 
introduced separately in the upper chamber of in vitro BBB model. EFV drug release was observed at different 
time points (30 min – Day 2) at the lower chamber of BBB model. A comparative analysis of sustained drug 
release from ND-EFV vs. FD through BBB was monitored with a drug content of the media with respect to 
time. Each set of drug release study was done in three replicates and data were represented with the statistical 
significance (p > 0.0001).
www.nature.com/scientificreports/
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ND-EFV had no significant effect on neuronal plasticity. In order to observe any deleterious effect 
of ND-EFV on neuron structural protein, we analyzed the expression of different synaptic plasticity genes in 
ND-EFV treated SK-N-MC as per published protocol37,38. Out of 84 human synaptic plasticity genes, we have 
observed significant up-regulation of three synaptic plasticity genes (CEBPD, EGR3, and GRIN1) in ND treated 
neuronal cells compared to control cells. We also observed significant down-regulation of GRM8 (3 fold), 
HOMER1 (4 fold), and IGF1 (4.8 fold) gene when compared to the untreated control cells (Fig. 7). Nonetheless, 
Fig. 7(d) gene-gene interaction analysis illustrated that all the genes that are affected by ND-EFV exposure are not 
directly related to each other with respect to their functional activity. Therefore, there was no connection between 
up-regulated or down-regulated genes. This observation over all indicated that there is no potential deleterious 
effect on neuronal plasticity of SK-N-MC in presence of ND-EFV. This finding also opens up a potential for the 
long-term use of ND-EFV without any side effects on human neurons.
Therapeutic efficacy study of ND-EFV. Anti-HIV-1 efficacy of ND-EFV was tested by introducing the 
formulation in HIV-1 infected primary human macrophages in vitro condition. Initially, Human peripheral blood 
mononuclear cells (PBMC) were isolated and incubated to be differentiated to macrophages. Following the dif-
ferentiation, cells were infected with HIV and FD and ND-EFV were introduced separately to HIV-1 infected 
macrophages. HIV-1 p24 level at cell supernatant of drug-treated cells indicated a significant difference on viral 
inhibition by unformulated EFV and ND-EFV. The effect of ND-EFV on HIV-1 replication was observed to be 
very effective and sustained over a period of seven days. In contrast, the unformulated EFV could control viral 
replication up to day five, thereafter, p24 returned to untreated levels. Infected and untreated macrophages were 
kept as positive controls. Overall representation in Fig. 8 confirmed the efficacy of ND-EFV over HIV-1 repli-
cation compared to unformulated EFV. This further demonstrated the promise of using ND-EFV for targeted 
drug delivery towards the CNS. Nonetheless, the present study did not confirm the direct CNS drug delivery of 
Figure 7. Human synaptic plasticity gene expression in ND-EFV exposed SK-N-MC cells. 84  genes analyzed 
that is related to the synaptic plasticity of the neurons through PCR array analysis. The only genes that 
significantly up (in red) /down (in blue) regulated (± ≥3 fold) are shown on the table. (a) 3D-profile of fold 
change of synaptic plasticity genes in ND exposed SK-N-MC cells. (b) Representative figures for scatter plot 
analysis of the changes in synaptic plasticity gene expression in ND-EFV exposed SK-N-MC cells: Spots 
associated with individual human synaptic plasticity gene were collected and converted into log10 scale. The 
central line indicates unchanged gene expression. The synaptic plasticity genes with expression levels higher or 
lower in treated neuronal cells than control cells are expected to produce dots that deviate from the centerline. 
The dots are allocated to positions that are above or below than the +3 fold or 3-fold line when the differences 
are greater than three folds. (c) Human synaptic plasticity genes expression in ND-EFV exposed SK-N-MC cells 
(fold change): Out of 84 genes analyzed, only genes significantly (± ≥ 3 fold) dysregulated were shown in this 
table (d) Gene-Gene interaction network for human synaptic plasticity genes dysregulated in ND-EFV exposed 
SK-N-MC cells.
www.nature.com/scientificreports/
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ND-EFV and possible consequences. In future, this formulation will be used to conjugate with a specific targeting 
agent (antibody, ligand, etc.) for direct drug delivery of anti-HIV-1 drugs to the CNS.
Discussion
EFV is one of the very effective NNRTIs that has been in use in present combined antiretroviral therapy (cART) 
for the treatment of HIV-1 infection. However, its low bioavailability, poor pharmacokinetics, and subsequent 
drug resistance have made it necessary to optimize therapeutic delivery agents to make EFV more targeted and 
effective39–41. Among the many nanocarbon materials that have been investigated for use as drug carriers, ND, is 
the most promising due to its many favorable properties, including, chemical inertness, biocompatibility, and easy 
availability compared to other nanocarbon materials17.
According to TEM study (Fig. 1A–C), nanodiamond particles have a spherical morphology and average par-
ticle size in a range of 5–6 nm that is close to vendor’s specifications (3–5 nm). As it should be expected, modifica-
tions of ND surface did not alter ND particles size, morphology or crystal structure (Fig. 1D). Raman spectra of 
all samples display the characteristic feature of the diamond phase (peak at 1326 cm−1). According to Mochalin 
et al., (2008) a broad feature around 1612 cm−1 can be assigned to graphitic carbon on ND surface (the G-band) 
with some contribution from hydroxyl groups that are chemo- or physisorbed onto the surface42. Considering 
the fact that cytotoxicity was one of the deciding factors for screening the right drug formulation for the neuronal 
cells, ROS and MTS assay was performed with all three formulations. As the neuronal cells are very sensitive to 
ROS, it was important to screen a formulation that does not induce significant amount of ROS production in the 
neuronal cells43. ROS study explained that ND-COOH can induce more ROS production than ND or ND-NH2.
Further study on cytotoxicity effect of all three formulations also established that ND-COOH was significantly 
toxic at a higher concentration above 40ug/ml. Following the surface modification and cell cytotoxicity study, ND, 
ND-COOH and ND-NH2 were loaded with EFV as per the protocol mentioned in the method. The EFV adsorp-
tion study on ND, ND-COOH, and ND-NH2 clearly indicated the potential of ND and ND-NH2 formulation 
over ND-COOH based on Lingmuir adsorption model. This observation also established the potential of ND and 
ND-NH2 over ND-COOH. Moreover, the dynamic stability of surface modified and unmodified ND were char-
acterized in sterile phosphate buffer saline (PBS), DMSO and in combination. Presently, the suspension stability 
was evaluated by visual observation in this study. Surface modified ND in these experiments had lower stability 
compared to unmodified ND. Unmodified ND was found to be stable for several hours in PBS suspensions and 
for several days in DMSO suspension (unpublished data). Experiments on further stability of ND/EFV suspen-
sions is in progress and will be reported elsewhere. In the present study, ND was suspended in 1:9 DMSO-PBS 
(volume/volume) for chemical characterization. The objective of the study was to find a formulation that is non-
toxic to neuronal cells and effective against HIV. In this regard, ND was found to be an ideal formulation because 
ND-COOH showed cytotoxicity and ND-NH2 had similar drug loading as ND. Considering all these factors, ND 
was selected for further characterization in vitro. In the dissolution study, ND-EFV demonstrated an extended 
release of EFV from drug formulation up to fourteen days indicating much more stable formulation than FD. The 
Figure 8. Therapeutic efficacy of ND-EFV on HIV-1 infected Macrophages. HIV replication was monitored 
in three different conditions. The HIV-infected cells that were kept untreated served as positive control (in 
red). HIV-infected cells were treated with unformulated EFV (40 µg/ml) served as reference (in blue). The 
ND-EFV (40 µg/ml) treated cells were considered as a test (in green). In all three sets of treatments, the p24 
level was monitored at a different time interval to measure the effect of treatment on HIV replication. In this 
case, 24h post infection was considered as day 0. Statistical significance was calculated with respect to p values 
(p < 0.0001).
www.nature.com/scientificreports/
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possible mechanism of FD release delay could be caused by sustained drug release from the reservoir effect in 
polymeric vehicles, which may attenuate with time and another retention effect from the dialysis bag itself. It is 
already reported that the dialysis bag may affect the in vitro drug release44. Therefore, even considering this delay 
impact from dialysis bag, the dissolution profile of ND-EFV was still observed to be adequate for sustained drug 
release requirement. EFV drug release study in BBB model also explained the potential benefit of ND-EFV over 
FD with respect to higher drug retention and delivery capacity to the brain which is one of the major impedi-
ments of targeted drug delivery. In this regard, it is worth mentioning that in vitro BBB membrane also present 
a concentration difference of FD between upper and lower chamber of the BBB model that might influence the 
faster release of FD to the media at the lower chamber. In addition, previous studies have also established the 
unformulated EFV exposure can disrupt the integrity of BBB and possible toxicity to BBB endothelial cells40,41. 
This might also allow more drug to pass through the BBB in a shorter period of time. The robust release of FD in 
the brain can also cause neurotoxicity and will get metabolized much faster upon release. Whereas, the sustained 
release of drug from nanoformulation will provide a constant control on viral replication in the brain with limited 
toxicity11. Since ND-EFV has demonstrated the stability of the biological environment and extended release of 
EFV crossing BBB, it provided a strong evidence to use this nanoformulation for anti-HIV drug development.
The present study also investigated the direct effect of ND-EFV on the expression of eighty-four key genes 
of neurons that are related to synaptic alteration during learning and memories. Alteration of these genes has a 
direct effect on some of the neuronal events like long-term potentiation (LTP), Long-term depression (LTD) etc. 
and those could be few potential side effects of ND-EFV. The synaptic plasticity gene array showed that there was 
no immediate side effect of ND-EFV on neuronal cells. This was also an important observation since unformu-
lated EFV has toxic effects on neurons and brain cells40,41. The therapeutic efficacy study also indicated that FD 
had an immediate effect on HIV replication. However, its efficacy significantly decreased within five days. On the 
other hand, ND-EFV could control viral replication up to seven days and beyond establishing further the suita-
bility of ND-EFV for long-term anti-HIV therapy.
The investigation of ND towards drug delivery and imaging has only begun very recently. Indeed, to our 
knowledge, the present study has shown for the first time the application of ND in targeted anti-HIV-1 drug deliv-
ery towards the CNS. Our study has established that ND-based nanodrugs are nontoxic to the CNS and specific 
molecular characterizations of these nanodrugs can cross the BBB to deliver drugs to the CNS. Most importantly, 
the initial chemical characterization of ND and the following biological characterization of ND-EFV has revealed 
a promising candidate for nanodrug delivery of anti-HIV-1 drugs to the CNS. However, the present study could 
not confirm the fate of the ND after EFV release since it was done in in vitro microenvironment. In the future, 
further in vivo study on ND-EFV will be performed to maximize its potential use as a therapeutic agent for HIV-1 
patients and its detailed metabolomics.
Methods
Cell culture and reagents. Human neuroblastoma cells (SK-N-MC) (ATCC Cat # HTB-10) were cul-
tured in Eagle’s minimum essential medium (MEM) (ATCC catalog # 30–2003) supplemented with fetal bovine 
serum to a final concentration of 10% (ATCC catalog # 30–2020). These cells and media were obtained from 
American Type Culture Collection, Manassas, VA and 1% antibiotic and antimycotic solution (catalog # A5955) 
was obtained from Sigma-Aldrich, St. Louis, MO. HIV-1 Ba-L (clade B) (Cat. # 510) was obtained through AIDS 
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. ND powder (3–6 nm, purity 97 + %) 
was purchased from Nanostructured and Amorphous Materials Inc. (Garland, TX, USA). EFV drug powder and 
all other chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA). An Agilent 1200 HPLC system 
(Palo Alto, CA) coupled to an Applied Biosystem 4000 Q TRAP quadrupole linear ion trap hybrid mass spec-
trometer (Applied Biosystems/MDS Sciex, Foster City, CA) was used for drug analysis. The HPLC-MSMS system 
is controlled by ChemStation and Analyst 1.4.2 software, respectively. All chromatographic separations were 
performed on an Agilent ZORBAX RP 18 column (3.5 µ, 150 mm × 0.5 mm) (Palo Alto, CA).
Characterization of nanodrug. Unmodified nanodiamond powder (ND) was used as it was for this study. 
Amine-functionalized nanodiamond (ND-NH2) was fabricated by the procedure reported45. 50 mg ND powder 
was dispersed in absolute ethanol via sonication for 30 min, and then, an excess solution of APTES was slowly 
dropped and stirred overnight at refluxing conditions on a water bath. The ND-NH2 was centrifuged and subse-
quently washed with ethanol for at least 5 times, which was then dried at 80 °C under vacuum for 12 h. Oxidation 
(surface modification with carboxyl-groups) was performed at 425 °C in air for 2 h46.
Transition electron microscopy (TEM). The preliminary characterization of the nanodrugs was per-
formed using a Phillips CM-200 200 kV Transmission Electron Microscope (TEM) with Energy Dispersive 
Spectroscopy (EDS) housed at FIU’s Advanced Materials Engineering Research Institute (AMERI). TEM obser-
vation was helpful for determining the particle size, morphology and dispersity of the nanodrugs.
X-ray diffraction (XRD). An X -ray diffraction study of ND was performed using a Bruker GADD/D8 
X-Ray diffraction system with Apex Smart CCD and imaging plate detectors and direct-drive rotating anode. The 
MacSci rotating anode (Molybdenum) operates at 50 kV voltages and 20 mA current. The 2D diffraction patterns 
obtained were integrated using Fit2D software47. This X-ray diffraction method was used for structural charac-
terization of the materials, particle size measurements of the crystalline phases, and for estimating the degree of 
crystallinity.
Raman spectroscopy characterization. A continuous wave (CW) argon ion (Ar+) laser (model 177G02, 
Spectra Physics) of 514.5 nm in wavelength was used as a source of monochromatic radiation. Backscattered 
Raman spectra were collected by a high-throughput holographic imaging spectrograph (Model HoloSpec f/1.8i, 
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Kaiser Optical Systems) with volume transmission gratings, a holographic notch filter, and a thermoelectrically 
cooled charge-coupled device CCD detector (Andor Technology). The Raman system has a spectral resolution of 
4 cm−1. The spectra were usually collected with 10 min exposure.
Reactive Oxygen Species (ROS) assay. ROS productions in SK-N-MC following exposure to differ-
ent concentrations of ND, ND-COOH, and ND-NH2 were detected using dichlorofluorescein diacetate assay 
(DCF-DA; Molecular Probes, Eugene, OR) as per previously published protocol48. Cells were cultured in 96-well 
plates (100,000 cells well) overnight to allow 70% confluence. The next day, cells were treated with different con-
centrations of ND, ND-COOH, ND-NH2 (10, 20, 40, 80, 100, 200, 400, 800, and 1000 µg/ml) for 24 h, respectively. 
The following day, cells were washed and pretreated with antioxidant, catalase (0.001 mg) for 2 h. After incuba-
tion, the cells were treated with DCF-DA (100uM) for 1 h at 37 °C, and finally, the cells were read in a BioTek 
Synergy HT microplate reader (excitation 485 nm and emission 528 nm; BioTek, Winooski, VT). Cells treated 
with H2O2 (50 µM) for 2 h were included as a positive control.
Cellular toxicity of nanodrug. Cytotoxicity of ND, ND-COOH, and ND-NH2 on SK-N-MC cells was 
determined via MTS assay (G3582, Promega, Madison, WI, USA)44. Cells were pre-incubated in 96-well plates 
with SK-N-MC cells and then treated with various concentrations of nanodrug (control, 0.5, 1, 2, 5, 10, 20, 40, 80, 
100, 200, 400, 800 and 1000 µg/ml) for 24 h at 37 °C. After treatment, cells were washed and incubated with fresh 
respective growth medium. Cells were further incubated with 20 µl of MTS reagent (CellTiter96® Aqueous One 
Solution, Madison, WI, USA) in complete 100 µl cell media for 1 h at 37 °C. Following incubation, an absorbance 
at 490 nm was measured using the BioTek plate reader (BioTek, Winooski, VT, USA). Untreated cells incubated 
with fresh media were used as a negative control. All measurements were taken as a mean of eight independent 
experimental values. The net absorbance (A) was taken as an index of cell viability. The cell viability was calcu-
lated as sample/control ×100%. The nanoformulations that did not cause more than 10% loss in cell viability after 
at least 24 hr exposure were considered nontoxic.
Drug adsorption study. In order to make the initial calibration curve, concentrations of 1:9 DMSO-PBS 
and EFV were made at 5, 40, 50, and 100 µg/ml from 10 mg/ml stock solution of EFV in a total volume of 2 ml 
for each concentration. The initial calibration curve was created using the absorbance values of the correspond-
ing concentrations (250 nm). The dilutions were thoroughly mixed and the optical density (OD) value of each 
concentration was measured twice using Hitachi U-2910 Spectrophotometer (UV Spec.) 2 mg of ND was then 
added to each glass tube. The tubes were then sonicated in an ultrasonic bath for 2 min. The tubes were then 
shaken at 25 °C and 190 rpm for approximately 24 h. The contents were then transferred to microfuge tubes and 
mixed using Eppendorf Thermomixer for 1h at 600 rpm. The solutions were then centrifuged at 13,000 rpm for 
1 h. The supernatant of the solutions was removed (conservatively), leaving the ND pellet. The OD values of the 
supernatant for each concentration were measured using Hitachi U-2910. Based on the measured absorbance 
values before and after the adsorption, the concentrations of drug in the resulting solutions were calculated using 
the measured OD values.
Drug analysis through HPLC-MS/MS. The EFV concentration in biological samples was quantitated by a 
previously reported Selected reaction monitoring (SRM) method49 In brief; the samples were homogenized with 
deionized H2O at a ratio of 1:2 (w/v). 1 mL of ice-cold acetonitrile was added to a 100 µL homogenized samples 
which spiked with 10 µL IS (2.0 g/mL lopinavir). The sample was then vortexed for 3 min, shaken for 15 min, and 
centrifuged at 16,000 × g for 10 min. The supernatant was aspirated, dried under vacuum at room temperature, 
and dissolved in 100 µL 50% methanol aqueous solvent. Before injection, the sample was centrifuged for 10 min 
at 16,000 g, 8 µL of supernatant was injected into the HPLC–MS/MS system for analysis. For all samples, the final 
concentration of IS was 200 ng/mL. The linearity of the method (in the range of 0.2–1000 ng/mL) was confirmed 
by preparing 3 standard curves on 3 different days.
Dissolution study of the ND-EFV. ND-EFV was tested for long-term sustained release capacity in physi-
ological buffer media. Briefly, a solution of ND-EFV nanoparticles (0.5 ml, concentration: 2 mg/20 mg ratio drug/
ND) was placed into a dialysis bag (molecular cutoff: 6 kDa), sealed, and put into a tube filled with 30–40 ml 
dissolution solution (composition: 0.1% Tween 20 PBS with pH 7.4). This concentration was decided based on 
the initial standardization of drug loading on ND through adsorption study (unpublished data). Dispersion of 
the ND-EFV in PBS (pH 7.4) was placed in the dialysis bag (D-bag) (Pur-A-Lyzer Maxi Dialysis Kit, SIGMA) 
and dialyzed against the respective buffer solution at 37 °C at a speed of 150 rpm. At each time (30 min, day-1, 
day-5 and day-14), 100 µl of the solution was taken out from the tank and the equal amount of fresh buffer was 
replenished. The free EFV release study was also measured in similar conditions simultaneously. Final drug con-
centrations of the collected samples were determined by HPLC as mentioned above.
Human synaptic plasticity RT2 profile PCR array. Synaptic plasticity gene expression profiling was 
done in SK-N-MC control (untreated) cells and ND-EFV (40ug/ml) treated cells for 24h using 96 well format RT2 
Profile PCR Array Human Synaptic Plasticity kit (SABiosciences, Cat. # PAHS-126Z) using Stratagene Mx3000p 
qRTPCR instrument37,38. This test includes 84 diverse genes important in human synaptic plasticity, includ-
ing Immediate-Early Response (n = 30), Late Response (n = 2), Long-Term Potentiation (n = 28), Long-Term 
Depression (n = 21), Cell Adhesion (n = 9), Extracellular Matrix & Proteolytic Processing (n = 5), CREB 
Cofactors (n = 10), Neuronal Receptors (n = 19), Postsynaptic Density (n = 15), as well as other genes involved 
in the synaptic plasticity (n = 2). Relative abundance of each mRNA species was assessed using RT2 SYBR Green/
ROX PCR Master mix (SABiosciences, Cat # 330520) and aliquoted in equal volumes (25 µl) to each well of 
the real-time PCR arrays. The real-time PCR cycling program (as indicated by the manufacturer) was run on a 
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Stratagene Mx3000p qRT-PCR thermal cycler. The threshold cycle (Ct) of each gene was determined by using the 
Stratagene MaxPro software. CT data was uploaded into the data analysis template on the manufacturer’s website 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). The relative expression of each gene in each 
ND-EFV treated group was compared with the expression in control cells and it was calculated on the website 
using the ∆∆ CT method with five housekeeping genes as controls. Controls are also included on each array for 
genomic DNA contamination, RNA quality, and general PCR performance. The result was represented in fold 
change in the expression in each gene of test and compared with control gene incorporating the statistical signif-
icance among the tested gene expression in the table form. The data also represented in 3D plot profile, scatter 
plot and volcano plot along with tabular form of up or down regulated gene expression. A gene-gene interactive 
analysis was also presented based on the level of expression including up & down regulation, co-expression, 
chemical modification and other protein related interaction. A direct gene-gene interaction would have indi-
cated by direct joined lines between two or more genes in the plot and no gene-gene interaction was indicated 
as no interconnecting lines between different genes spots within the plot. This observation presents the valuable 
information about functional co-relation of different up and down regulated genes with respect to their function 
related to neuroplasticity.
Drug delivery through BBB. Primary Human Brain Microvascular Endothelial Cells (HBMVEC) and 
astrocytes were obtained from Science Research Laboratories, Carlsbad, CA. In vitro BBB model was established 
in the trans-well plate as per published protocol50,51. HBMVEC was inoculated at the upper side of 0.4 um pore 
size PTFE membrane tissue culture inserts (Corning, NY) at an initial concentration of 104 cells/well. A confluent 
layer of human astrocytes was grown on the lower side of the membrane. After incubation, the integrity of the BBB 
was measured with transendothelial electrical resistance (TEER) using Millicell ERS microelectrodes (Millipore, 
Billerica, MA, USA). The typical TEER values of untreated BBB were observed to be around ~200 Ω/cm2. 
For the drug delivery study, HBMVEC were allowed to grow up to 70% confluency and then ND-EFV (40 µg/ml) 
was introduced into the upper chamber of the transwell insert. Following that, media was collected at different 
time points (30 min, 1 h, Day-1, and Day-2) from the lower chamber and replenished with fresh media. The drug 
content of the collected media was measured by HPLC as mentioned above. Simultaneously, the unformulated 
drug was also introduced in a similar setup and monitored for drug release with respect to the time period.
Therapeutic efficacy. ND-EFV was investigated for anti-HIV-1 efficacy in the primary human mac-
rophage as previously published protocol48. Human PBMC were obtained from a healthy subject through pur-
chase from a local clinic and differentiated into macrophages as previously published49. PBMC were isolated with 
Ficoll-Hypaque (Pharmacia) gradient and cells were incubated for differentiation for 7 days in the presence of 
human macrophage colony stimulating factor (MCSF, Sigma) to macrophages. Following incubation, macrophages 
were infected with HIV-1 1Ba-L (NIH AIDS research and reference reagent program Cat# 510) (100 ng/ml) 
for 24 h. Following 24 h of infection (day 0), cells were washed to get rid of any unattached virus and fresh media 
was added. At the same time, 40 µg/ml of ND-EFV and FD was added separately to these cells in two different 
setups. The HIV-1 infected macrophages served as a positive control. The ND-EFV/ FD-treated cells were mon-
itored for up to 10 days along with infected control cells. The cell supernatant was collected at day 0, 1, 2, 3, 5, 
and 7 days post-treatment. The viral p24 level in the supernatant was measured with p24 ELISA assay (Cat. # 
0801200, Zeptometrix, USA). The p24 level at different time points provided the level of viral inhibition caused 
by ND-EFV and FD. The p24 level at the culture supernatant will be inversely proportional to the therapeutic 
efficacy of ND-EFV.
Statistical analysis. Experiments were performed in multiple replicates and the data were presented as 
mean ± SEM. The statistical significance of each experiment was analyzed by two-tailed paired t-test and with 
one & two-way ANOVA test with GraphPad Prism software (GraphPad Prism Software Inc. San Diego, CA) and 
a p-value of ≤0.05 was considered as significant.
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